Cibc Asset Management Inc Allakos Inc. Transaction History

Cibc Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$8.55 - $111.89 $18,279 - $239,220	-2,138 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$76.53 - $110.43 $163,621 - $236,099	2,138 New	2,138 $226,000
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $164,934 - $220,441	-1,932 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$109.73 - $153.66 $13,825 - $19,361	126 Added 6.98%	1,932 $222,000
Q4 2020 Feb 03, 2021	BUY	$79.58 - $152.45 $143,721 - $275,324	1,806 New	1,806 $253,000

105

77.4M

70.7K

2.8K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $71.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.